Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Maintains Target Price $8
Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Cuts Target Price to $8
Cytek Biosciences Analyst Ratings
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8
Cytek Biosciences: Hold Rating Amidst Mixed Performance and Cautious U.S. Market Outlook
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Maintains Target Price $12
Cytek Biosciences: Poised for Turnaround Despite Q2 Setbacks, Analyst Maintains Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Piper Sandler: Maintaining the Cytek Biosciences (CTKB.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $10.00 to $8.50.
Cytek Biosciences Analyst Ratings
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8.5
Cytek Biosciences (CTKB) Receives a Buy From Piper Sandler
Cytek Biosciences Analyst Ratings
Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)
Goldman Sachs Maintains Buy on Cytek Biosciences, Raises Price Target to $10
Cytek Biosciences (CTKB) Gets a Buy From Piper Sandler
Cytek Biosciences: A Strong Buy Rating Backed by Solid Financials and Strategic Growth Initiatives
TD Cowen Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)
Piper Sandler Keeps Their Buy Rating on Cytek Biosciences (CTKB)